logo
GameChange Solar Expands LATAM Footprint with Eight New Solar Projects Totaling 715 MWp

GameChange Solar Expands LATAM Footprint with Eight New Solar Projects Totaling 715 MWp

Cision Canada23-06-2025
NORWALK, Conn., June 23, 2025 /CNW/ -- GameChange Solar announced a significant expansion in Latin America today with eight new solar projects, including three in Chile, one in El Salvador, and four in Colombia, totaling 715 MWp. GameChange Solar's continued growth demonstrates the ability to provide high-performance tracker and fixed-tilt systems optimized for diverse geotechnical and climatic conditions in Latin America's evolving energy infrastructure.
The projects include seven with Genius Tracker™ single-axis trackers and one with a MaxSpan™ fixed-tilt system. The breadth of projects illustrates the adaptability, performance and reliability of GameChange Solar's technology in diverse and challenging environments, including the extreme desert conditions of Chile's Antofagasta region, complex soil conditions in El Salvador, and the corrosive and expansive soil conditions in the Caribbean region of Colombia.
" These projects highlight the trust our customers place in GameChange Solar's technology to deliver reliable, high-performance systems in some of the toughest environments in the world," said Juan Gonzalez, Director of Business Development for LATAM. "From the deserts of Chile to the tropical coasts of Colombia, our solutions are helping to drive clean energy adoption across Latin America."
GameChange Solar continues to build momentum in the region as solar project developers look for proven partners to deliver speed, durability, and value.
About GameChange Solar
GameChange is one of the top three global providers of solar tracker solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. We have delivered over 43 GW of solar trackers and fixed tilt systems that combine fast installation, bankable quality, and unbeatable value through superior engineering, innovative design, and high-volume manufacturing. Our products enable solar panels at power plants to follow the sun's movement across the sky and optimize plant performance while protecting the array from damaging weather conditions. For more information, visit www.gamechangesolar.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Absci Announces Pricing of Public Offering of Common Stock
Absci Announces Pricing of Public Offering of Common Stock

Globe and Mail

timean hour ago

  • Globe and Mail

Absci Announces Pricing of Public Offering of Common Stock

VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) ('Absci'), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci. Absci intends to use the net proceeds from the offering to fund the advancement of its internally developed programs, continued investment in its Integrated Drug Creation™ platform, and for working capital and other general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are acting as joint book-running managers for the offering. The offering is expected to close on or about July 25, 2025, subject to the satisfaction of customary closing conditions. The shares of common stock are being offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267043) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on August 24, 2022 and became effective on September 2, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on July 24, 2025. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone: (866) 718-1649, or by email at prospectus@ J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@ and postsalemanualrequests@ Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@ TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297- 2926, or by email at or by accessing the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Absci's anticipated public offering. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions, statements about the expected gross proceeds from the offering and use of proceeds, and the completion of the offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Absci's Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Absci's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the public offering filed with the SEC. In addition, any forward-looking statements contained in this press release represent Absci's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Absci explicitly disclaims any obligation to update any forward-looking statements, except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Kiwetinohk announces upcoming second quarter 2025 earnings release
Kiwetinohk announces upcoming second quarter 2025 earnings release

Globe and Mail

time3 hours ago

  • Globe and Mail

Kiwetinohk announces upcoming second quarter 2025 earnings release

CALGARY, AB , July 24, 2025 /CNW/ - Kiwetinohk Energy Corp. (TSX: KEC) management will host a conference call on July 31, 2025 , at 8 AM MT ( 10 AM ET ) to discuss second quarter 2025 results and answer questions. Participants can listen to the conference call by dialing 1-888-510-2154 ( North America toll free) or 437-900-0527 ( Toronto and area). A replay of the call will be available until August 7, 2025 , at 1-888-660-6345 ( North America toll free) or 646-517-4150 ( Toronto and area) by using the code 92805. About Kiwetinohk Kiwetinohk produces natural gas, natural gas liquids, oil and condensate from profitable early to mid-life liquids-rich natural gas properties focused in the Montney and Duvernay formations in Alberta, Canada . Kiwetinohk's common shares trade on the Toronto Stock Exchange under the symbol KEC. Additional details are available on Kiwetinohk's website at and SEDAR+ at For more information on Kiwetinohk, please contact: Investor Relations Investor Relations email: IR@ Investor Relations phone: (587) 392-4395 Pat Carlson , Chief Executive Officer Jakub Brogowski, Chief Financial Officer

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store